Article
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Gastroenterology - 1 Apr 2012
Andersen Jesper B, Spee Bart, Blechacz Boris R, Avital Itzhak, Komuta Mina, Barbour Andrew, Conner Elizabeth A, Gillen Matthew C, Roskams Tania, Roberts Lewis R, Factor Valentina M, Thorgeirsson Snorri S
Abstract excerpt
BACKGROUND & AIMS: Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy. METHODS: We profiled the transcriptomes from 104 surgically resected cholangiocarcinoma samples collected from patients in Australia, Europe, and the United States;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.